370 results on '"Witteles, Ronald M."'
Search Results
2. Tyrosine kinase inhibitor–associated ventricular arrhythmias: a case series and review of literature
3. Abstract 18390: Ibrutinib Increases Ventricular Arrhythmia Burden Independently of Atrial Arrhythmia
4. Abstract 16577: Unraveling T-cell and Macrophage Chemokine Crosstalk in Immunotherapy-Induced Myocarditis
5. Abstract 16450: Increased Monocyte Count and Neutrophil-to-Lymphocyte Ratio With ICI Myocarditis
6. Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer
7. A Retrospective Analysis of Medical Student Performance Evaluations, 2014–2020: Recommend with Reservations
8. Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias
9. Improvements in Efficacy Measures With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
10. Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation
11. The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity
12. Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC
13. Effect of Tafamidis on Renal Function in Patients With Transthyretin Amyloid Cardiomyopathy in ATTR-ACT
14. Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis: JACC: CardioOncology Primer
15. Racial and Ethnic Disparities in Cardio-Oncology: A Call to Action
16. Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation
17. Organ responses with daratumumab therapy in previously treated AL amyloidosis
18. A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis
19. Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias
20. Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
21. AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management
22. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice
23. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy
24. Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis
25. Generation of two induced pluripotent stem cell lines from hereditary amyloidosis patients with polyneuropathy carrying heterozygous transthyretin (TTR) mutation
26. Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation
27. Development and validation of a rapid visual technique for left ventricular hypertrophy detection from the electrocardiogram
28. Advances in the Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy
29. Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response
30. Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty
31. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response
32. Abstract 14859: Mesenchymal Stem Cells Rescue Patient-Specific Cardiomyocyte Viability and Function Following Doxorubicin Injury via Microvesicle Mediated Mitochondrial Transfer to Recapitulate Human Clinical Trial Results
33. Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors
34. Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies
35. Emerging Therapies for Transthyretin Cardiac Amyloidosis
36. ESC Cardio-Oncology Guidelines
37. Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy
38. Tyrosine kinase inhibitor–associated ventricular arrhythmias: a case series and review of literature
39. Cancer Therapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis
40. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
41. Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis
42. Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group
43. Drug Development for Transthyretin Amyloidosis: Time to Fix the System?
44. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
45. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society
46. Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor: A Case Report
47. Capecitabine-Induced Chest Pain Relieved by Diltiazem
48. Dipeptidyl Peptidase 4 Inhibition Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy
49. LATE ONSET IMMUNOTHERAPY-INDUCED MYOCARDITIS TWO YEARS AFTER CHECKPOINT INHIBITOR INITIATION
50. Constrictive Pericarditis Revealing Rare Case of ALH Amyloidosis With Underlying Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.